Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials

CMAJ. Canadian Medical Association Journal

Volumn 170, Issue 9, 2004, Pages 1395-

  Wooltorton, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; LICENSING; MIXED DEPRESSION AND DEMENTIA; MORBIDITY; MULTIINFARCT DEMENTIA; SHORT SURVEY;

EID: 2342628427     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1040539     Document Type: Short Survey

References (4)

1. Choice of an antipsychotic. Med Letter 2003;45:102-4.
2. Wooltorton E. Risperidone (Risperdal). increased rate of cerebrovascular events in dementia trials. CMAJ 2004;167(11):1269-70.
3. 2004 safety alert: Zyprexa (olanzapine). Washington: US Food and Drug Administration; 2004 Mar 1. Available: www.fda.gov/medwatch/SAFETY/2004/zyprexa. htm (accessed 2004 Apr 1).
4. Olanzapine (Zyprexa) and cerebrovascular